{"entity":{"id":"enb003","kind":"drug","name":"ENB003","aka":[],"tldr":"ENB003 is a small-molecule antagonist from ENB Therapeutics, Inc, in registered phase 2 trials for melanoma.","summary":"ENB003 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by ENB Therapeutics, Inc, in melanoma. Described in the registry record as a nb003 is selective endothelin b receptor antagonist; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-2","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of ENB003","url":"https://clinicaltrials.gov/search?intr=ENB003"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04205227"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"code":"ENB003","modality":"Small-molecule antagonist","mechanism":"Described in the registry record as a nb003 is selective endothelin b receptor antagonist; the trial entries below carry the sponsor's wording.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/enb003/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"trial":[{"id":"nct04205227","kind":"trial","name":"ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors","route":"/trials/nct04205227/"}]}}